Drug development hit by war
Abstract
Introduction: Drug development is the process by which academic, pharmaceutical, or government laboratories identify or screen new chemical entities to find potentially active pharmacological compounds and bring them to the market. This process is undoubtedly the heart and soul of modern medicine. War is an incidental condition that can disrupt the drug development pipeline and clinical research. During the current Russia-Ukraine war, multiple sanctions are being imposed on Russia which is disrupting the supply chain and slowing down the process of drug development.
Objective: This review was done to understand how war and international conflicts affect the global drug development process.
Methods: Information was obtained by reviewing the data from previously published news material. We used PubMed, Google Scholar, Web of Science, Medline, and Embase as our search engines and keywords like (Ukraine, Russia, clinical trial, pharmaceutical industry, war, and drug development). In total, we reviewed 74 articles, and the obtained information was interpreted, compiled, evaluated, reassembled, deconstructed and conclusions were reached.
Conclusion: In the past despite multiple wars, mankind has not learned from their past mistakes. The pharmaceutical industry should form mitigation plans so that in the time of crisis other options are available for drug discovery and clinical research.
References
Browne, G. (2022)a. The War Puts Ukraine's Clinical Trials—and Patients—in Jeopardy. Retrieved 3 April 2022, from https://www.wired.co.uk/article/war-ukraine-clinical-trials-jeopardy
Browne, G. (2022)b. Big Pharma's Ethical Dilemma: Should They Keep Selling to Russia?. Retrieved 3 April 2022, from https://www.wired.co.uk/article/big-pharma-faces-an-ethical-dilemma-should-they-keep-selling-to-russia#intcid=_wired-uk-bottom-recirc_918fa474-c358-40ef-b249-193b66276644_entity-topic-similarity-v2
Castaneda, R. (2022)a. Ukraine: Industry-sponsored clinical development at risk. Retrieved 3 April 2022, from https://www.clinicaltrialsarena.com/analysis/ukraine-industry-sponsored-clinical-trial-development-at-risk/
Castaneda, R. (2022)b. Clinical trials in Russia: drug development pipeline at risk. Retrieved 3 April 2022, from https://www.clinicaltrialsarena.com/special-focus/ukraine-crisis/clinical-trials-in-russia-at-risk/
Ellis, R. (2022). Pharmaceutical Companies Cutting Ties With Russia. Retrieved 3 April 2022, from https://www.webmd.com/drug-medication/news/20220315/pharmaceutical-companies-cutting-ties-with-russia
Fishchuk, R. (2022). ‘He will die’: Russia-Ukraine war’s unseen medical horrors. Retrieved 3 April 2022, from https://www.aljazeera.com/features/2022/3/16/ukraine-if-they-move-her-son-from-intensive-care-he-will-die
GlaxoSmithKline says it will not start any new clinical trials in Russia. (2022). Retrieved 3 April 2022, from https://www.theguardian.com/business/2022/mar/17/glaxosmithkline-says-it-will-not-start-any-new-clinical-trials-in-russia
Hughes, J. P., Rees, S., Kalindjian, S. B., & Philpott, K. L. (2011). Principles of early drug discovery. British journal of pharmacology, 162(6), 1239–1249.
How Russia's invasion of Ukraine could affect 200+ clinical trials. (2022). Retrieved 3 April 2022, from https://www.advisory.com/daily-briefing/2022/02/25/russia-ukraine
Home - ClinicalTrials.gov. (2022). Retrieved 10 April 2022, from https://www.clinicaltrials.gov/
Khan, T. (2022). After Effects of Russia - Ukraine Conflict Over Pharma and Life Sciences Industry. Retrieved 3 April 2022, from https://pharmashots.com/7033/after-effects-of-russia-ukraine-conflict-over-pharma-and-life-sciences-industry
LaHucik, K., Armstrong, A., Bayer, M., Sagonowsky, E., & Dunleavy, K. (2022). UPDATED: Biotech leaders call on industry to cut ties with Russia amid Ukraine invasion. Retrieved 3 April 2022, from. https://www.fiercebiotech.com/biotech/russian-invasion-ukraine-could-impact-more-200-clinical-trials-sites-european-country
Liu, A., Sagonowsky, E., & Kansteiner, F. (2022). AbbVie, Eli Lilly, Novartis and more cut back in Russia amid corporate exodus over Ukraine war. Retrieved 3 April 2022, from https://www.fiercepharma.com/pharma/abbvie-eli-lilly-novartis-and-more-cut-back-russia-amid-corporate-exodus-over-ukraine-crisis
Pfizer Updates Company Position in Russia | Pfizer. (2022). Retrieved 3 April 2022, from https://www.pfizer.com/news/press-release/press-release-detail/pfizer-updates-company-position-russia.
Pharmaceutical industry response to the war in Ukraine. (2022). Retrieved 3 April 2022, from https://www.efpia.eu/news-events/the-efpia-view/efpia-news/pharmaceutical-industry-response-to-the-war-in-ukraine/
Rajgopal, D. (2022). Biz as usual for Indian pharma cos despite Russia-Ukraine war. Retrieved 3 April 2022, from https://www.livemint.com/companies/biz-as-usual-for-indian-pharma-cos-despite-russia-ukraine-war-11647889982207.html
Russia’s war in Ukraine is killing cancer care in both countries. (2022). BMJ. 376.
Stewart, A. (2022). “We Want to Return to the Lab”: How the Russian Invasion Has Disrupted Drug Discovery in Ukraine. Retrieved 3 April 2022, from https://themedicinemaker.com/discovery-development/we-want-to-return-to-the-lab-how-the-russian-invasion-has-disrupted-drug-discovery-in-ukraine
Copyright (c) 2022 Hara Prasad Mishra, Ayush Goel, Sahil Kumar, Mihir Chauhan, Mrinal Patnaik, Imaad Rehman
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
